A recent study evaluates the efficacy of MEK inhibitors in treating high-grade gliomas associated with neurofibromatosis type 1 (NF1). The findings indicate partial responses in a single-institution cohort, contributing to the understanding of treatment options for this rare disease.

A multi-country survey reveals healthcare providers' perspectives on managing adults with neurofibromatosis type 1 and plexiform neurofibroma. The findings highlight current practices and challenges in treatment approaches.

A recent study explores the clinical characteristics and treatment strategies for brainstem lesions in children with neurofibromatosis type 1. This research contributes to understanding the complexities of managing this rare condition.

At FDA Rare Disease Day 2026, leaders emphasized the importance of patient-centered innovations and new regulatory pathways to accelerate treatments for rare diseases like neurofibromatosis type 1 (NF1) and pediatric cancers. The event highlighted the role of urgency and flexibility in drug development, aiming to improve options for families affected by these conditions.